SG11201403179QA - Use of n-hydroxysuccinimide to improve conjugate stability - Google Patents
Use of n-hydroxysuccinimide to improve conjugate stabilityInfo
- Publication number
- SG11201403179QA SG11201403179QA SG11201403179QA SG11201403179QA SG11201403179QA SG 11201403179Q A SG11201403179Q A SG 11201403179QA SG 11201403179Q A SG11201403179Q A SG 11201403179QA SG 11201403179Q A SG11201403179Q A SG 11201403179QA SG 11201403179Q A SG11201403179Q A SG 11201403179QA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxysuccinimide
- conjugate stability
- improve conjugate
- improve
- stability
- Prior art date
Links
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570139P | 2011-12-13 | 2011-12-13 | |
PCT/US2012/069527 WO2013090590A1 (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201403179QA true SG11201403179QA (en) | 2014-07-30 |
Family
ID=48613179
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201604747WA SG10201604747WA (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
SG11201403179QA SG11201403179QA (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201604747WA SG10201604747WA (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
Country Status (14)
Country | Link |
---|---|
US (1) | US20140350228A1 (en) |
EP (1) | EP2790724A4 (en) |
JP (1) | JP2015504869A (en) |
KR (1) | KR20140107418A (en) |
CN (1) | CN104093425A (en) |
AU (1) | AU2012352210A1 (en) |
BR (1) | BR112014014464A8 (en) |
CA (1) | CA2859444A1 (en) |
EA (1) | EA201491173A1 (en) |
HK (1) | HK1203364A1 (en) |
IL (1) | IL233086A0 (en) |
MX (1) | MX2014007125A (en) |
SG (2) | SG10201604747WA (en) |
WO (1) | WO2013090590A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006283726C1 (en) | 2005-08-24 | 2015-05-07 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
SI2691155T1 (en) | 2011-03-29 | 2019-03-29 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
SG10201702737TA (en) | 2012-10-04 | 2017-05-30 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
JP6744212B2 (en) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Enzymatic binding of polypeptides |
CN106267225B (en) * | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | Trimaleimide-type linker and use thereof |
CN109152845B (en) | 2016-04-14 | 2022-07-12 | 宝力泰锐克斯有限公司 | Comprising at least two (-CH) s within a ring2-CH2Conjugates of linkers of-O-) units and conjugation reagents |
GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
CN113336823A (en) * | 2021-05-28 | 2021-09-03 | 联宁(苏州)生物制药有限公司 | Synthetic method for antibody-conjugated drug linker LND1067 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2835829B1 (en) * | 2002-02-13 | 2007-09-14 | Centre Nat Rech Scient | NOVEL PROCESS FOR THE PREPARATION OF DNA OR PROTEIN BIOPUCES AND THEIR APPLICATIONS |
DE10242076A1 (en) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | New covalently bonded conjugates of hydroxyalkyl starch with allergens, useful as modified allergens with depot effect for use in specific immunotherapy for combating allergies, e.g. hay fever |
AU2006283726C1 (en) * | 2005-08-24 | 2015-05-07 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
EP2298308B1 (en) * | 2005-11-14 | 2013-01-16 | University Of Southern California | Integrin-binding small molecules |
ES2435779T3 (en) * | 2007-07-19 | 2013-12-23 | Sanofi | Cytotoxic agents comprising new tomaimycin derivatives and their therapeutic use |
IL271761B (en) * | 2009-02-05 | 2022-09-01 | Immunogen Inc | (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepin-6-one, 4-benzyloxy-5-methoxy-2-nitrobenzoic acid and processes for preparing the same |
SG10201810743WA (en) * | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
-
2012
- 2012-12-13 AU AU2012352210A patent/AU2012352210A1/en not_active Abandoned
- 2012-12-13 WO PCT/US2012/069527 patent/WO2013090590A1/en active Application Filing
- 2012-12-13 CA CA 2859444 patent/CA2859444A1/en not_active Abandoned
- 2012-12-13 EA EA201491173A patent/EA201491173A1/en unknown
- 2012-12-13 MX MX2014007125A patent/MX2014007125A/en unknown
- 2012-12-13 BR BR112014014464A patent/BR112014014464A8/en not_active IP Right Cessation
- 2012-12-13 SG SG10201604747WA patent/SG10201604747WA/en unknown
- 2012-12-13 EP EP12856692.4A patent/EP2790724A4/en not_active Withdrawn
- 2012-12-13 JP JP2014547433A patent/JP2015504869A/en active Pending
- 2012-12-13 US US14/365,305 patent/US20140350228A1/en not_active Abandoned
- 2012-12-13 KR KR20147019143A patent/KR20140107418A/en not_active Application Discontinuation
- 2012-12-13 SG SG11201403179QA patent/SG11201403179QA/en unknown
- 2012-12-13 CN CN201280068773.2A patent/CN104093425A/en active Pending
-
2014
- 2014-06-12 IL IL233086A patent/IL233086A0/en unknown
-
2015
- 2015-04-21 HK HK15103864.0A patent/HK1203364A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL233086A0 (en) | 2014-07-31 |
MX2014007125A (en) | 2015-04-16 |
JP2015504869A (en) | 2015-02-16 |
EP2790724A4 (en) | 2015-08-05 |
CA2859444A1 (en) | 2013-06-20 |
KR20140107418A (en) | 2014-09-04 |
WO2013090590A1 (en) | 2013-06-20 |
HK1203364A1 (en) | 2015-10-30 |
EP2790724A1 (en) | 2014-10-22 |
BR112014014464A2 (en) | 2017-06-13 |
CN104093425A (en) | 2014-10-08 |
AU2012352210A1 (en) | 2014-07-24 |
US20140350228A1 (en) | 2014-11-27 |
SG10201604747WA (en) | 2016-08-30 |
EA201491173A1 (en) | 2014-11-28 |
BR112014014464A8 (en) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190576T1 (en) | Methods of preparation of conjugates | |
HK1244183A1 (en) | Deuterated derivatives of ivacaftor | |
IL265707A (en) | Pharmaceutical compositions comprising human antibodies to pcsk9 | |
HK1203364A1 (en) | Use of n-hydroxysuccinimide to improve conjugate stability n- | |
HUE047354T2 (en) | Deuterated derivatives of ivacaftor | |
HK1197068A1 (en) | Methods for preparation of glycosphingolipids and uses thereof | |
EP2665733A4 (en) | Preparation of metal-triazolate frameworks | |
EP2892998A4 (en) | Methods of tissue generation | |
EP2892577A4 (en) | Methods of tissue generation | |
EP2670761A4 (en) | Preparation of metal-catecholate frameworks | |
EP2764325A4 (en) | Using videogrammetry to fabricate parts | |
EP2852403A4 (en) | Methods for modification of tissues | |
IL236312A0 (en) | Preparation of 18f-fluciclovine | |
GB2491882B (en) | Improvements to letterboxes | |
EP2684869A4 (en) | Preparation of 3-mercaptopropionates | |
EP2758421A4 (en) | Compositions and methods related to tissue targeting | |
PL395425A1 (en) | Preparation of 2-amino-N-tert-butyl-2-cyanoacetamide hydrochloride | |
GB201104632D0 (en) | Use of medicament | |
PL395618A1 (en) | Device for enhancing stability of muscle fibers | |
PT3326648T (en) | Pharmaceutical compositions comprising human antibodies to pcsk9 | |
GB201113502D0 (en) | Synthesis preparation and formation of shiphonated lirocene | |
IL212131A0 (en) | Two halves of ahearf are joimed to test acoople's comptisility | |
UA22469S (en) | DETAIL OF SHAPED COMPRESSION TEE BODY |